Basb 205 polypeptides and polynucleotides from haemophilus influenzae

Abstract

The invention provides BASB205 polypeptides and polynucleotides encoding BASB205 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

1 . An isolated polypeptide comprising an amino acid sequence selected from:
 (a) the amino acid sequence selected from SEQ ID NO:4, 6, 8 and 12; and   (b) an amino acid sequence which has at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 10, over the entire length of said sequence; and   (c) the amino acid sequence set forth in SEQ ID NO:10.   
     
     
         2 . The isolated polypeptide of  claim 1 , consisting of the amino acid sequence selected from SEQ ID NO: 4, 6, 8, 10 and 12. 
     
     
         3 . An immunogenic fragment of a polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from SEQ ID NO: 2, 4, 6, 8, 10 and 12, over the entire length of said sequence, wherein said fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognizes a polypeptide of SEQ ID NO: 4, 6, 8, 10 or 12. 
     
     
         4 . The isolated polypeptide of  claim 1 , wherein said polypeptide is part of a larger fusion protein. 
     
     
         5 . An isolated polynucleotide encoding the polypeptide of  claim 1 . 
     
     
         6 . An isolated polynucleotide comprising a nucleotide sequence complementary to the isolated polynucleotide of  claim 5 . 
     
     
         7 . The isolated polynucleotide of  claim 5 , comprising a nucleotide sequence selected from SEQ ID NO: 1, 3, 5, 7, 9, and 11; or a nucleotide sequence complementary to said isolated polynucleotide. 
     
     
         8 . An expression vector or a recombinant live microorganism comprising the isolated polynucleotide according to  claim 5 . 
     
     
         9 . A host cell comprising the expression vector of  claim 8 , or a subcellular fraction or a membrane of said host cell. 
     
     
         10 . A process for producing a polypeptide expressed by the host cell of  claim 9 , comprising culturing the host cell under conditions sufficient for production of the polypeptide and recovering the polypeptide from the culture medium. 
     
     
         11 . A process for expressing the isolated polynucleotide of  claim 5  comprising transforming a host cell with an expression vector comprising said polynucleotide and culturing said host cell under conditions sufficient for expression of said polynucleotide. 
     
     
         12 . An immunogenic composition comprising an effective amount of the immunogenic fragment of  claim 3 , and a pharmaceutically acceptable carrier. 
     
     
         13 . An immunogenic composition comprising (a) a pharmaceutically acceptable carrier and (b)(i) an effective amount of the isolated polypeptide of  claim 1 ; (ii) an effective amount of an immunogenic fragment of the isolated polypeptide of  claim 1 ; or (iii) an effective amount of a polypeptide comprising an amino acid sequence at least 85% identical to the amino acid sequence set forth in SEQ ID NO:2, 4, 6, 8, 10, or 12. 
     
     
         14 . An immunogenic composition comprising an effective amount of the polynucleotide of  claim 5 , and a pharmaceutically acceptable carrier. 
     
     
         15 . The immunogenic composition according to  claim 12 , wherein said composition comprises at least one other non typeable  Haemophilus influenzae  antigen. 
     
     
         16 . An isolated antibody immunospecific for the polypeptide of  claim 1 , or an immunological fragment of the isolated antibody. 
     
     
         17 . A method of diagnosing a non typeable  Haemophilus influenzae  infection, comprising identifying a polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from SEQ ID NO: 2, 4, 6, 8, 10 and 12, over the entire length of said sequence, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having a non typeable  H. influenzae  infection. 
     
     
         18 . A therapeutic composition for treating humans with non typeable  Haemophilus influenzae  disease comprising the isolated antibody of  claim 16  and a suitable pharmaceutical carrier. 
     
     
         19 . A method of generating an immune response in an animal, comprising administering the immunogenic composition of  claim 13  to the animal. 
     
     
         20 . A method of generating an immune response in an animal, comprising administering to the animal (a) the immunogenic composition of  claim 14 ; or (b) an immunogenic composition comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence which has at least 85% identity to the nucleotide sequence selected from SEQ ID NO: 1, 3, 5, 7, 9 and 11, over the entire length of said sequence.